| 18/05/26 | 16:30:00 | 18 May 2026 | | Name Change, Board Change and Company Update |
| 30/04/26 | 15:33:40 | 30 Apr 2026 | | Total Voting Rights & Update of Fundraising |
| 24/04/26 | 14:51:23 | 24 Apr 2026 | | Holding(s) in Company |
| 20/04/26 | 16:39:07 | 20 Apr 2026 | | BOARD APPOINTMENT, FUND RAISE & OPTION AGREEMENTS |
| 30/01/26 | 11:50:50 | 30 Jan 2026 | | Interim Results to 31 October 2025 |
| 02/12/25 | 10:24:00 | 2 Dec 2025 | | Symposium: Shortwave Presenting Clinical Research |
| 02/12/25 | 07:00:11 | 2 Dec 2025 | | Result of AGM, TVR and Shares Correction |
| 06/11/25 | 07:00:12 | 6 Nov 2025 | | Patent Application Publication |
| 04/11/25 | 11:34:48 | 4 Nov 2025 | | AGM, Treasury Policy & Capital Reorganisation |
| 31/10/25 | 15:25:14 | 31 Oct 2025 | | ANNUAL REPORT AND ACCOUNTS TO 30 APRIL 2025 |
| 15/10/25 | 15:44:35 | 15 Oct 2025 | | Appointment of Aquis Corporate Adviser |
| 26/09/25 | 07:00:12 | 26 Sept 2025 | | Appointment digital asset treasury partner Archax |
| 10/09/25 | 07:00:14 | 10 Sept 2025 | | Direction, Director Changes and Medical Adviser |
| 19/08/25 | 12:50:10 | 19 Aug 2025 | | Holding(s) in Company |
| 04/08/25 | 11:00:00 | 4 Aug 2025 | | Clarification on Strategic Advisor Appointment |
| 29/07/25 | 07:00:13 | 29 Jul 2025 | | £250k Fundraising, New Directors & Review |
| 24/06/25 | 13:10:17 | 24 Jun 2025 | | AQSE Only - Holding(s) in Company |
| 16/06/25 | 10:21:44 | 16 Jun 2025 | | Holding(s) in Company |
| 10/06/25 | 07:00:13 | 10 Jun 2025 | | £40,000 Placing |
| 31/01/25 | 16:52:08 | 31 Jan 2025 | | Interim Results to 31 October 2024 |
| 23/12/24 | 12:00:00 | 23 Dec 2024 | | Pre-Crowdfunding re Groundbreaking Treatment |
| 29/11/24 | 15:16:03 | 29 Nov 2024 | | Total Voting Rights |
| 27/11/24 | 14:12:18 | 27 Nov 2024 | | Director Appointment and SPA Update |
| 31/10/24 | 17:39:42 | 31 Oct 2024 | | YEAR ENDED 30 APRIL 2024 AND DIRECTOR RESIGNATION |
| 19/09/24 | 07:00:08 | 19 Sept 2024 | | Positive Pre-Clinical Result Drive to Human Trials |
| 31/07/24 | 12:05:18 | 31 Jul 2024 | | Total Voting Rights |
| 17/07/24 | 17:20:48 | 17 Jul 2024 | | TR1: Notification of Major Holdings |
| 08/07/24 | 07:00:12 | 8 Jul 2024 | | Company’s Patent Claims Confirmed |
| 03/07/24 | 15:49:19 | 3 Jul 2024 | | Holding(s) in Company |
| 12/06/24 | 15:00:00 | 12 Jun 2024 | | Holding(s) in Company |
| 06/06/24 | 07:00:13 | 6 Jun 2024 | | Name Change Rebranding and Share Option Update |
| 05/04/24 | 14:00:00 | 5 Apr 2024 | | Board Resignation, Role Change and Option Grant |
| 01/03/24 | 14:10:40 | 1 Mar 2024 | | Total Voting Rights |
| 02/02/24 | 07:00:06 | 2 Feb 2024 | | Operational Update, Share Options and Share Issue |
| 30/01/24 | 07:00:12 | 30 Jan 2024 | | Interim Results to 31 October 2023 |
| 01/12/23 | 08:50:00 | 1 Dec 2023 | | Holding(s) in Company |
| 30/11/23 | 16:14:07 | 30 Nov 2023 | | Total Voting Rights |
| 07/11/23 | 07:00:16 | 7 Nov 2023 | | Board Changes and Shortwave Pharma Completion |
| 31/10/23 | 12:04:51 | 31 Oct 2023 | | AUDITED RESULTS FOR THE YEAR ENDED 30 APRIL 2023 |
| 07/07/23 | 08:00:01 | 7 Jul 2023 | | PSYCH Symposium 2023 |
| 22/06/23 | 07:00:08 | 22 Jun 2023 | | PSYCH Symposium 2023: 6th July 2023 |
| 19/06/23 | 07:00:04 | 19 Jun 2023 | | Acquisition of Short Wave Pharma for £3.5m |
| 25/04/23 | 07:00:11 | 25 Apr 2023 | | PSYCH SYMPOSIUM 6th JULY, LONDON |
| 31/01/23 | 15:03:04 | 31 Jan 2023 | | Interim Results to 31 October 2022 |
| 28/11/22 | 14:43:12 | 28 Nov 2022 | | Result of AGM |
| 04/11/22 | 15:48:51 | 4 Nov 2022 | | Notice of Annual General Meeting |
| 31/10/22 | 16:04:07 | 31 Oct 2022 | | AUDITED RESULTS TO 30 APRIL 2022 |
| 20/10/22 | 07:00:05 | 20 Oct 2022 | | Drug Reform Group Representative Appointment |
| 16/08/22 | 07:00:12 | 16 Aug 2022 | | Awakn Expands Commercial Operations Into The U.S |
| 21/07/22 | 12:47:23 | 21 Jul 2022 | | Awakn Phase III Trial receives CA$2.5m funding |
